论文部分内容阅读
目的:探讨新型口服抗凝药治疗高龄非瓣膜性心房颤动患者抗凝治疗有效性及安全性。方法:选择2016年3月至2018年9月浙江绿城心血管病医院收治的高龄非瓣膜性心房颤动患者176例，根据患者治疗情况将其分为华法林组56例、达比加群酯组64例、利伐沙班组56例。三组患者均连续治疗6个月，比较三组患者栓塞事件及出血事件发生率、治疗前后血糖以及肝肾功能指标变化情况。结果:华法林组、达比加群酯组、利伐沙班组血栓栓塞事件发生率分别为7.14%(4/56)、1.56%(1/64)、3.57%(2/56)，差异无统计学意义(n U＝2.457，n P>0.05)。华法林组、达比加群酯组、利伐沙班组出血发生率分别为16.07%(9/56)、3.13%(2/64)、1.79%(1/56)，差异有统计学意义(n U＝11.090，n P0.05). The incidences of bleeding in the warfarin group, dabiga group and rivaroxaban group were 16.07%(9/56), 3.13%(2/64), 1.79%(1/56), respectively, there was statistically significant difference among the three groups(n U=11.090, n P<0.05), which in the warfarin group was significantly higher than that in the dabicarbonate group and rivaroxaban group(χn 2=6.012, 7.028, all n P0.05).n Conclusion:Compared with warfarin, the new oral anticoagulant dapigatron ester and rivaroxaban have similar effects in preventing stroke and thromboembolism in elderly patients with non-valvular atrial fibrillation, while the risk of bleeding events during the administration of dapigatron ester and rivaroxaban is lower, suggesting that the new oral anticoagulant is effective in the treatment of stroke and thromboembolism in elderly patients with non-valvular atrial fibrillation.The therapy has high efficacy and safety, which is worthy of clinical promotion.